Tokyo/Works/Assay0

From 2007.igem.org

(Difference between revisions)
(Procedure:)
Line 26: Line 26:
===Procedure:===
===Procedure:===
<br>[[Tokyo/AHL assay Standard protocol |AHL assay Standard protocol ]]
<br>[[Tokyo/AHL assay Standard protocol |AHL assay Standard protocol ]]
 +
 +
===Results and Conclusion===
 +
[[Image:hybridgraph2.JPG|thumb|350px| '''Fig.1: '''Result]]
[[Image:hybridgraph2.JPG|thumb|350px| '''Fig.1: '''Result]]
[[Image:hybridgraph.JPG|thumb|300px| '''Fig.2: '''Result summary]]
[[Image:hybridgraph.JPG|thumb|300px| '''Fig.2: '''Result summary]]

Revision as of 13:05, 24 October 2007


Works top  0. Hybrid promoter  1. Formulation  2. Assay1  3. Simulation  4. Assay2  5. Future works

Purpose 1:

To check if LacI hybrid promoter is activated by AHL and repressed by LacI.

Purpose 2:

To obtain parameters of LacI hybrid promoter for computational simulation.

Samples:


1. pTrc99A + [LacI hybrid promoter – GFP] (LacI+)
2. pBR322 TetR + [LacI hybrid promoter – GFP] (lacI-)
3. pTrc99A + [placQI – GFP] (placQI is constitutive promoter)
4. pTrc99A + [LacI promoter – GFP]
5. pBR322 TetR + [LacI promoter – GFP]


Repressor LacI expression:
pTrc99A expresses LacI
pBR322 TetR does NOT express LacI


Antibiotics resistance:
pTrc99A gives ampicillin-resistance
pBR322 TetR gives ampicillin-resistance
[LacI hybrid promoter – GFP] gives kanamicin-resistance
[placQI – GFP] gives kanamicin-resistance

Procedure:


AHL assay Standard protocol

Results and Conclusion

Fig.1: Result
Fig.2: Result summary